You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials

Article metrics

Article menu

Download PDFPDF

XML
Treatments
Original article
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials

 

Online download statistics by month:

Online download statistics by month: May 2019 to March 2023

AbstractFullPdf
May 2019383818
Jun 2019351326128
Jul 2019311310126
Aug 2019412408110
Sep 201923223148
Oct 201919619758
Nov 201915915375
Dec 2019828141
Jan 202011311251
Feb 2020909043
Mar 2020929253
Apr 20206564137
May 2020626261
Jun 2020636043
Jul 20209488113
Aug 2020535171
Sep 2020786488
Oct 202017517262
Nov 2020675943
Dec 2020675836
Jan 2021858025
Feb 202110710366
Mar 2021857464
Apr 2021726336
May 2021938944
Jun 2021706435
Jul 202112311142
Aug 2021958739
Sep 202110510335
Oct 202113612957
Nov 2021645647
Dec 2021158146109
Jan 2022818144
Feb 20221009438
Mar 202212912139
Apr 202213613261
May 202216716963
Jun 202218918085
Jul 2022888537
Aug 202216315973
Sep 202215614537
Oct 202219317959
Nov 202216315972
Dec 202213312768
Jan 202315314863
Feb 202319819374
Total604257932817